[1]汪青,黄昊强,陈勇,等.二仙汤在绝经后骨质疏松症肾阳虚证治疗中的应用价值及作用机制研究[J].中医正骨,2022,34(03):8-14.
　WANG Qing,HUANG Haoqiang,CHEN Yong,et al.Applied values and mechanism of action of oral application of Erxian Tang(二仙汤)in treatment of postmenopausal osteoporosis with syndrome of kidney-yang deficiency:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(03):8-14.
点击复制

二仙汤在绝经后骨质疏松症肾阳虚证治疗中的应用价值及作用机制研究()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第34卷
期数:
2022年03期
页码:
8-14
栏目:
临床研究
出版日期:
2022-03-20

文章信息/Info

Title:
Applied values and mechanism of action of oral application of Erxian Tang(二仙汤)in treatment of postmenopausal osteoporosis with syndrome of kidney-yang deficiency:a clinical study
作者:
汪青; 黄昊强; 陈勇; 陈吉; 洪嵘
(昆山市中医医院,江苏 昆山 215300)
Author(s):
WANG Qing; HUANG Haoqiang; CHEN Yong; CHEN Ji; HONG Rong
Kunshan Hospital of Chinese Medicine,Kunshan 215300,Jiangsu,China
关键词:
骨质疏松; 绝经后;  二仙汤;  肾阳虚;  碳酸钙;  阿法骨化醇;  背痛;  骨密度;  骨钙素;  Ⅰ型前胶原氨基端前肽;  Ⅰ型胶原羧基端肽β特殊序列;  钙;  磷;  miR-335-5p;  临床试验
Keywords:
osteoporosis; postmenopausal;  Erxian Tang;  syndrome of deficiency of kidney yang;  calcium carbonate;  alfacalcidol;  back pain;  bone density;  osteocalcin;  N-terminal propeptide of typeⅠprecollagen;  β C-terminal telopeptide of type Ⅰ collagen;  calcium;  phosphorus;  miR-335-5p;  clinical trial
摘要:
目的:探讨二仙汤在绝经后骨质疏松症肾阳虚证治疗中的应用价值,并探讨其作用机制。方法:将90例绝经后骨质疏松症肾阳虚证患者随机分为2组,每组45例,分别采用口服二仙汤联合碳酸钙D3和阿法骨化醇软胶囊(二仙汤组)与单纯碳酸钙D3和阿法骨化醇软胶囊(基础用药组)治疗。碳酸钙D3,每日1次,每次1片; 阿法骨化醇软胶囊,每日1次,每次1粒; 二仙汤,每日2次,每次1袋,早晚服用; 均连续服用12周。分别于治疗前和治疗结束后,采用疼痛视觉模拟量表(visual analogue scale,VAS)评分评价腰背部疼痛情况,采用双能X线骨密度仪测定患者腰椎(L1～L4)骨密度及股骨颈骨密度,采用酶联免疫吸附法测定血清骨钙素、Ⅰ型前胶原氨基端前肽(N-terminal propeptide of typeⅠprecollagen,PⅠNP)及Ⅰ型胶原羧基端肽β特殊序列(β C-terminal telopeptide of type Ⅰ collagen,β-CTX)含量,采用化学发光法测定血钙及血磷含量,采用荧光定量PCR法测定血清miR-335-5p的表达量。结果:①受试者退出情况。共10例患者退出试验,其中二仙汤组3例因未能按时按计量服药退出,2例因失访退出; 基础用药组1例因未能按时按计量服药退出,4例因失访退出。②腰背部疼痛VAS评分。治疗前,2组患者腰背部疼痛VAS评分比较,差异无统计学意义[(4.03±0.80)分,(3.90±0.93)分,t=0.645,P=0.521]; 治疗结束后,二仙汤组腰背部疼痛VAS评分低于基础用药组[(2.10±0.87)分,(2.98±1.10)分,t=-3.526,P=0.001],2组患者腰背部疼痛VAS评分均低于治疗前(t=14.198,P=0.000; t=7.656,P=0.000)。③骨密度。治疗前与治疗结束后,2组患者腰椎骨密度和股骨颈骨密度比较,组间差异均无统计学意义[腰椎:(0.886±0.040)g·cm-2,(0.880±0.030)g·cm-2,t=0.746,P=0.458;(0.888±0.040)g·cm-2,(0.878±0.030)g·cm-2,t=0.994,P=0.323。股骨颈:(0.763±0.070)g·cm-2,(0.767±0.070)g·cm-2,t=-0.263,P=0.794;(0.765±0.070)g·cm-2,(0.770±0.070)g·cm-2,t=-0.927,P=0.360]; 治疗结束后2组患者腰椎骨密度和股骨颈骨密度与治疗前比较,差异均无统计学意义(腰椎:t=-1.099,P=0.281; t=0.701,P=0.492。股骨颈:t=-1.640,P=0.109; t=-0.927,P=0.360)。④骨代谢生化指标。治疗前,2组患者血清骨钙素含量比较,差异无统计学意义[(14.09±3.97)ng·mL-1,(15.56±3.67)ng·mL-1,t=-1.070,P=0.092]; 治疗结束后,2组患者血清骨钙素含量的差异无统计学意义[(16.14±3.67)ng·mL-1,(15.58±4.74)ng·mL-1,t=0.602,P=0.549],二仙汤组患者血清骨钙素含量高于治疗前(t=-11.325,P=0.000),基础用药组患者血清骨钙素含量与治疗前的差异无统计学意义(t=0.045,P=0.964)。治疗前,2组患者血清PⅠNP含量比较,差异无统计学意义[(38.08±11.90)ng·mL-1,(36.90±9.80)ng·mL-1,t=0.484,P=0.630]; 治疗结束后,二仙汤组患者血清PⅠNP含量高于基础用药组[(45.96±13.38)ng·mL-1,(35.43±12.15)ng·mL-1,t=3.684,P=0.000],二仙汤组患者血清PⅠNP含量高于治疗前(t=-10.795,P=0.000),基础用药组患者血清PⅠNP含量与治疗前的差异无统计学意义(t=1.564,P=0.126)。治疗前与治疗结束后,2组患者血清β-CTX含量比较,组间差异均无统计学意义[(0.36±0.10)ng·mL-1,(0.36±0.09)ng·mL-1,t=0.140,P=0.889;(0.38±0.11)ng·mL-1,(0.37±0.10)ng·mL-1,t=0.499,P=0.619]; 治疗结束后2组患者血清β-CTX含量与治疗前比较,差异均无统计学意义(t=-1.279,P=0.209; t=-1.004,P=0.322)。治疗前与治疗结束后,2组患者血磷、血钙含量比较,组间差异均无统计学意义[(血磷:(1.27±0.14)mmol·L-1,(1.23±0.12)mmol·L-1,t=1.415,P=0.161;(1.25±0.08)mmol·L-1,(1.23±0.12)mmol·L-1,t=1.277,P=0.206。血钙:(2.33±0.08)mmol·L-1,(2.32±0.07)mmol·L-1,t=0.659,P=0.512;(2.34±0.06)mmol·L-1,(2.35±0.06)mmol·L-1,t=-0.514,P=0.608]; 治疗结束后2组患者血磷、血钙含量与治疗前比较,差异均无统计学意义(血磷:t=0.799,P=0.419; t=0.197,P=0.845。血钙:t=-0.401,P=0.690; t=-1.552,P=0.129)。⑤血清miR-335-5p表达量。治疗前,2组患者血清miR-335-5p的表达量比较,差异无统计学意义(1.04±0.72,1.06±0.66,t=-0.081,P=0.936); 治疗结束后,二仙汤组血清miR-335-5p的表达量高于基础用药组(7.71±1.94,1.36±0.83,t=14.520,P=0.000),且高于治疗前(t=-17.289,P=0.000),基础用药组血清miR-335-5p的表达量与治疗前的差异无统计学意义(t=-1.279,P=0.216)。结论:口服二仙汤有利于缓解绝经后骨质疏松症肾阳虚证患者的腰背痛和促进骨形成,其作用机制可能与上调miR-335-5p的表达有关。
Abstract:
Objective:To explore the applied values of oral application of Erxian Tang(二仙汤,EXT)in treatment of postmenopausal osteoporosis(PMOP)with kidney-yang deficiency syndrome(KYDS),and to explore its mechanism of action.Methods:Ninety PMOP patients with KYDS were enrolled in the study and were randomly divided into EXT group and basic medication group,45 cases in each group.The patients in EXT group were treated with oral applications of EXT(twice a day in the morning and evening respectively,1 bag at a time),calcium carbonate and Vitamin D3 tablets(once a day,1 tablet at a time)and alfacalcidol soft capsules(once a day,1 capsule at a time)for consecutive 12 weeks; while the ones in basic medication group were merely with oral applications of calcium carbonate and Vitamin D3 tablets and alfacalcidol soft capsules for consecutive 12 weeks.The low back pain was evaluated by using pain visual analogue scale(VAS)score,and the bone mineral density(BMD)of lumbar vertebra(LV)from L1 to L4 and femoral neck(FN),the serum levels of osteocalcin(OCN),N-terminal propeptide of typeⅠprecollagen(PⅠNP)and β C-terminal telopeptide of typeⅠcollagen(β-CTX),the levels of serum calcium(Ca)and serum phosphorus(P)and the expression level of serum miR-335-5p were detected by using dual-energy X-ray absorptiometry(DEXA),enzyme linked immunosorbent assay(ELISA),chemiluminescence immunoassay(CLIA)and fluorescent quantitative PCR method respectively before the treatment and after the end of the treatment.Results:①Three patients in EXT group and 1 case in basic medication group dropped out of the study for failing to take medication as required,while 2 cases in EXT group and 4 cases in basic medication group dropped out of the study for losing to follow-up.②There was no statistical difference in low back pain VAS score between the 2 groups before the treatment(4.03±0.80 vs 3.90±0.93 points,t=0.645,P=0.521).The low back pain VAS scores were lower in EXT group compared to basic medication group after the end of the treatment(2.10±0.87 vs 2.98±1.10 points,t=-3.526,P=0.001),and it decreased after the end of treatment compared to pretreatment in the 2 groups(t=14.198,P=0.000; t=7.656,P=0.000).③There was no statistical difference in BMD of LV from L1 to L4 and FN between the 2 groups before the treatment and after the end of the treatment(LV:0.886±0.040 vs 0.880±0.030 g/cm(2),t=0.746,P=0.458; 0.888±0.040 vs 0.878±0.030 g/cm(2),t=0.994,P=0.323.FN:0.763±0.070 vs 0.767±0.070 g/cm(2),t=-0.263,P=0.794; 0.765±0.070 vs 0.770±0.070 g/cm(2),t=-0.927,P=0.360),and there was no statistical difference between the 2 timepoints in the 2 groups(LV:t=-1.099,P=0.281; t=0.701,P=0.492.FN:t=-1.640,P=0.109; t=-0.927,P=0.360).④There was no statistical difference in serum level of OCN between the 2 groups before the treatment and after the end of the treatment(14.09±3.97 vs 15.56±3.67 ng/mL,t=-1.070,P=0.092; 16.14±3.67 vs 15.58±4.74 ng/mL,t=0.602,P=0.549).The serum level of OCN was higher after the end of treatment compared to pretreatment in EXT group(t=-11.325,P=0.000),while the differences in serum level of OCN were not statistically significant between the 2 timepoints in basic medication group(t=0.045,P=0.964).There was no statistical difference in serum level of PⅠNP between the 2 groups before the treatment(38.08±11.90 vs 36.90±9.80 ng/mL,t=0.484,P=0.630).The serum level of PⅠNP was higher in EXT group compared to basic medication group after the end of treatment(45.96±13.38 vs 35.43±12.15 ng/mL,t=3.684; P=0.000),and it was higher after the end of treatment compared to pretreatment in EXT group(t=-10.795,P=0.000),while there was no statistical difference between the 2 timepoints in basic medication group(t=1.564,P=0.126).There was no statistical difference in serum level of β-CTX between the 2 groups before the treatment and after the end of treatment(0.36±0.10 vs 0.36±0.09 ng/mL,t=0.140,P=0.889; 0.38±0.11 vs 0.37±0.10 ng/mL,t=0.499,P=0.619),and there was no statistical difference in serum level of β-CTX between the 2 timepoints in the 2 groups(t=-1.279,P=0.209; t=-1.004,P=0.322).There was no statistical difference in the levels of serum P and serum Ca between the 2 groups before the treatment and after the end of treatment(serum P:1.27±0.14 vs 1.23±0.12 mmol/L,t=1.415,P=0.161; 1.25±0.08 vs 1.23±0.12 mmol/L,t=1.277,P=0.206.serum Ca:2.33±0.08 vs 2.32±0.07 mmol/L,t=0.659,P=0.512; 2.34±0.06 vs 2.35±0.06 mmol/L,t=-0.514,P=0.608),and there was no statistical difference in levels of serum P and serum Ca between the 2 timepoints in the 2 groups(serum P:t=0.799,P=0.419; t=0.197,P=0.845.serum Ca:t=-0.401,P=0.690; t=-1.552,P=0.129).⑤There was no statistical difference in the expression level of serum miR-335-5p between the 2 groups before the treatment(1.04±0.72 vs 1.06±0.66,t=-0.081,P=0.936).The expression level of serum miR-335-5p was higher in EXT group compared to basic medication group after the end of treatment(7.71±1.94 vs 1.36±0.83,t=14.520,P=0.000),and it was higher after the end of treatment compared to pre-treatment in EXT group(t=-17.289,P=0.000),wheres there was no statistical difference in the expression level of serum miR-335-5p between the 2 timepoints in basic medication group(t=-1.279,P=0.216).Conclusion:Oral application of EXT is helpful to relieve low back pain and promote bone formation in PMOP patients with KYDS,and its mechanism of action may be that it can up-regulate the expression of miR-335-5p.

参考文献/References:

[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.
[2] 梁伟乔,钟诚,李宇明.骨质疏松症的中医病因病机认识与治疗进展[J].中国骨质疏松杂志,2020,26(1):135-139.
[3] 陈世洲,毛国庆.二仙汤及加减方治疗骨质疏松症的研究进展[J].中国骨质疏松杂志,2018,24(12):1644-1646.
[4] 中国老年学和老年医学学会骨质疏松分会中医药专家委员会.中医药防治原发性骨质疏松症专家共识(2020)[J].中国骨质疏松杂志,2020,26(12):1717-1725.
[5] 陈元川,庞坚,詹红生.骨质疏松症慢性疼痛机制的研究进展[J].医学综述,2020,26(7):1249-1253.
[6] ALOUMANIS K,MAVROUDIS K.The “depressive” face of osteoporosis and the “osteoporotic” face of depression[J].Hormones(Athens),2013,12(3):350-362.
[7] ASMUS S E,PARSONS S,LANDIS S C.Developmental changes in the transmitter properties of sympathetic neurons that innervate the periosteum[J].J Neurosci,2000,20(4):1495-1504.
[8] PAOLUCCI T,SARACENI V M,PICCININI G.Management of chronic pain in osteoporosis:challenges and solutions[J].J Pain Res,2016,9:177-186.
[9] 杨颖,陈名道,李凤英,等.二仙汤及其拆方对GT1-7细胞株GnRH分泌的影响[J].中国中西医结合急救杂志,2001,8(3):143-145.
[10] 龙小平.二仙汤加减对围绝经期抑郁症患者症状及内分泌指标改善的疗效分析[J].四川中医,2018,36(8):169-172.
[11] 罗武龙,陈洁,牛婕,等.基于网络药理学的二仙汤治疗抑郁症的作用机制研究[J].中国药理学通报,2020,36(9):1317-1324.
[12] 许凤全,郑瑀,许琳洁,等.加味二仙汤联合心理疏导对更年期抑郁症女性单胺类神经递质的影响[J].中国中西医结合杂志,2017,37(7):789-794.
[13] 张萌萌,张岩,吴涤,等.骨代谢生化指标实验推荐方案[J].中国骨质疏松杂志,2021,27(10):1405-1412.
[14] 中华医学会骨质疏松和骨矿盐疾病分会.骨转换生化标志物临床应用指南[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(4):321-336.
[15] BAUER D C.Clinical Use of Bone Turnover Markers[J].JAMA,2019,322(6):569-570.
[16] MIURA M.Evaluation of bone for using of bone metabolic markers in the diagnosis and treatment of osteoporosis[J].Clin Calcium,2013,23(3):325-338.
[17] MCCLUNG M R,SAN MARTIN J,MILLER P D,et al.Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass[J].Arch Intern Med,2005,165(15):1762-1768.
[18] 范中正,董万涛,刘保健,等.MicroRNA通过肠道菌群对绝经后骨质疏松症影响的机制探讨[J].中国微生态学杂志,2021,33(9):1100-1103.
[19] 贾敏,蒋跃绒,苗阳.microRNA在中医证候诊断、疗效评价及预后研究中的应用进展[J].中国中西医结合杂志,2018,38(5):636-639.
[20] 涂玥,万毅刚,顾一煌,等.非编码RNA调控自噬的分子机制及中药的干预作用[J].中国中药杂志,2019,44(21):4545-4551.
[21] 李济伶,冯正平,陈力学,等.miR-335-5 p对高糖状态下成骨细胞功能的影响[J].中华内分泌代谢杂志,2015,31(8):712-716.
[22] ZHANG J,TU Q,BONEWALD L F,et al.Effects of miR-335-5p in modulating osteogenic differentiation by speci-fically downregulating Wnt antagonist DKK1[J].J Bone Miner Res,2011,26(8):1953-1963.
[23] ZHANG L,TANG Y,ZHU X,et al.Overexpression of mir-335-5p promotes bone formation and regeneration in mice[J].J Bone Miner Res,2017,32(12):2466-2475.
[24] 黄振明,蔡卓,钱静,等.微小RNA-335-5p调控BMP-2对人BMSCs成骨分化的影响[J].中国修复重建外科杂志,2020,34(6):781-786.
(收稿日期:2021-12-01 本文编辑:时红磊)

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):12.
[3]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[4]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):27.
[5]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):19.
[6]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):20.
[7]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):5.
[8]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):21.
[9]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(03):16.
[10]许超,肖鲁伟,吴承亮.绝经后女性骨质疏松症辨证分型与抑郁焦虑的关系研究[J].中医正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(03):3.
[11]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):7.
[12]欧国峰,刘鑫,董博,等.绝经后骨质疏松症的免疫学研究进展[J].中医正骨,2016,28(08):70.
[13]施振宇,刘钟,陈文亮,等.中医综合疗法防治绝经后骨量减少的多中心临床研究[J].中医正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(03):1.
[14]梁文娜,李西海,李灿东.血清microRNA与绝经后骨质疏松症肾虚证的关系[J].中医正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制绝经后骨质疏松大鼠骨代谢紊乱的作用机制研究[J].中医正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(03):1.
[16]刘晨,李兴勇,姚兴璋,等.绝经后骨质疏松症的流行病学概况及发病机制研究进展[J].中医正骨,2018,30(03):52.
[17]杨依然,刘钟,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路参与绝经后骨质疏松症发生发展过程中细胞自噬的机制[J].中医正骨,2018,30(04):59.
[18]曹俊青,郑剑南,张麟.右归丸联合阿仑膦酸钠口服治疗绝经后骨质疏松症肾阳虚证的临床研究[J].中医正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右归丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(03):20.
[19]李中万,徐绍俊,杨广钢,等.健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证[J].中医正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(03):11.
[20]赵凡,刘全,吴连国.口服强骨饮联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[J].中医正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(强骨饮)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(03):26.

备注/Memo

备注/Memo:
基金项目:苏州市2020年度第二十九批科技发展计划(民生科技-医疗卫生应用基础研究)项目(SYS2020065) 通讯作者:洪嵘 E-mail:605019963@qq.com
更新日期/Last Update: 1900-01-01